ArticleCardio-oncology (London, England)2026
Evaluating the impact of Lutetium-177 therapy on bioprosthetic heart valves in carcinoid heart disease.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere carcinoid heart disease (CaHD) may require bioprosthetic valve (BPV) replacement. Lutetium-177 (Lu-177) DOTATATE is increasingly utilized in patients with neuroendocrine tumors (NETs); however, its effect on BPVs remains unknown.
methodsA retrospective review of patients with CaHD who underwent BPV replacement at three tertiary centers in the United States was conducted. Patients were stratified by Lu-177 DOTATATE therapy with a propensity-matched non-exposed cohort. BPV degeneration and mortality were compared.
resultsOf 183 patients with CaHD and BPV replacement (median age 62.9 years, 50.8% male), 27 received Lu-177 DOTATATE (16 postoperatively, 11 preoperatively). BPVs treated with Lu-177 DOTATATE postoperatively demonstrated increased BPV degeneration (HR 4.42, 95%CI 3.29–5.93, p < 0.001). BPVs in patients preoperatively exposed to Lu-177 DOTATATE showed no difference in degeneration. There was no difference in mortality in those treated or not treated with Lu-177 DOTATATE.
conclusionsOur findings suggest an association between postoperative Lu-177 DOTATATE and increased BPV degeneration in CaHD patients. Where feasible, therapy prior to valve replacement should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.